arrow
J

Javier Pascual

hospital universitario virgen de la victoria
H指数:16
被引数:2,038

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

A randomized controlled trial of CDK7 inhibitor samuraciclib plus fulvestrant in advanced HR+/HER2− breast cancer

CDK7抑制剂Samuraciclib联合氟维司群治疗晚期HR+/HER2−乳腺癌的随机对照试验

2026-10-050
OAAI
Whole-genome sequencing of Reed-Sternberg cells identifies outcome determinants in Hodgkin lymphoma

对里德-斯泰伯格细胞的基因组测序确定了霍奇金淋巴瘤的预后决定因素

2026-09-040
OA
Real-world data analysis of adjuvant capecitabine for triple-negative breast cancer after neoadjuvant chemotherapy

新辅助化疗后三阴性乳腺癌辅助卡培他滨的真实世界数据分析

2025-11-180
OAAI
Patient-reported outcomes in the SERENA-6 trial of camizestrant plus CDK4/6 inhibitor in patients with advanced breast cancer and emergent ESR1 mutations during first-line endocrine-based therapy

SERENA-6试验中,卡米泽斯特ант联合CDK4/6抑制剂治疗在初次内分泌治疗期间出现ESR1突变的晚期乳腺癌患者的患者报告结局。

2025-10-200
OAAI
Increased blood draws for ultrasensitive ctDNA and CTCs detection in early breast cancer patients
2024-05-151
OAAI
The prognostic and predictive impact of circulating tumour DNA (ctDNA) dynamics in patients with metastatic Triple Negative Breast Cancer (TNBC) on olaparib based therapy: Results from Cohort E of the PlasmaMATCH trial
2024-05-020
PRE
NK cell-triggered CCL5/IFNγ-CXCL9/10 axis underlies the clinical efficacy of neoadjuvant anti-HER2 antibodies in breast cancer
2024-01-035
OAAI
Comparative study of droplet-digital PCR and absolute Q digital PCR for ctDNA detection in early-stage breast cancer patients
2024-01-015
OAAI
Baseline Mutations and ctDNA Dynamics as Prognostic and Predictive Factors in ER-Positive/HER2-Negative Metastatic Breast Cancer Patients
2023-07-256
OAAI
Increasing blood volumes to detect minimal residual disease in neoadjuvant-treated early breast cancer patients
2023-04-040
PRE
CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2-Metastatic Breast Cancer

CCNE1和PLK1介导HR /HER2-Metastatic乳腺癌对Palbociclib的耐药性

2023-02-0716
OAAI
ESMO recommendations on the use of circulating tumour DNA assays for patients with cancer: a report from the ESMO Precision Medicine Working Group

ESMO关于癌症患者使用循环肿瘤DNA检测的建议: 来自ESMO精准医学工作组的报告

2022-08-01264
OA
Adaptive immunity and neutralizing antibodies against SARS-CoV-2 variants of concern following vaccination in patients with cancer: the CAPTURE study
2021-10-27130
OAAI
Triplet Therapy with Palbociclib, Taselisib, and fulvestrant in PIK3CA-Mutant Breast Cancer and Doublet Palbociclib and Taselisib in Pathway-Mutant Solid Cancers
2021-01-0645
OAAI
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance
2020-02-0383
OAAI